Phase 2 Study of TVB-2640 in KRAS Non-Small Cell Lung Carcinomas
NCT03808558
·
clinicaltrials.gov ↗
PHASE2
Phase
ACTIVE_NOT_RECRUITING
Status
18
Enrollment
OTHER
Sponsor class
Conditions
KRAS Gene Mutation
Interventions
DRUG:
TVB-2640
Sponsor
David E Gerber
Collaborators
[object Object]
[object Object]
[object Object]